New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
05:05 EDTVNDAVanda Pharmaceuticals receives negative opinion from CHMP on Fanaptum
Vanda Pharmaceuticals announced that the European Medicines Agency's Committee for Medicinal Product for Human Use, or CHMP, has issued a negative opinion recommending against approval of Fanaptum for the treatment of schizophrenia in adult patients in the European Union. The CHMP was of the opinion that the benefits of Fanaptum did not outweigh its risks and recommended against marketing authorization at this point in time. Vanda intends to appeal this opinion and request a re-examination of the decision by the CHMP.
News For VNDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 25, 2015
10:37 EDTVNDAOptions with decreasing implied volatility
Options with decreasing implied volatility: FUEL GREK NLNK HLSS SLXP LL VNDA AWAY DWA TRUE
February 24, 2015
10:08 EDTVNDAOptions with decreasing implied volatility
Subscribe for More Information
February 23, 2015
10:17 EDTVNDAOptions with decreasing implied volatility
Subscribe for More Information
February 19, 2015
09:12 EDTVNDAOn The Fly: Pre-market Movers
Subscribe for More Information
07:09 EDTVNDAVanda sees FY15 sales of Hetlioz and Fanapt $95M-$110M
Subscribe for More Information
07:08 EDTVNDAVanda reports Q4 adjusted EPS (36c), two estimates (20c)
Reports Q4 revenue $15.37M, two estimates $16.15M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use